CIK 0001799788 · Non-accelerated filer<br>Smaller reporting company
Greenwich LifeSciences, Inc.
Sign in to watch- Ticker
- GLSI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205473709
- Phone
- 203-434-3290
- Business address
- 3992 BLUEBONNET DR, BUILDING 14, STAFFORD, TX, 77477
- 4 Open-market buy CEO and CFO bought 2,300 shares at $9.26 ($21,298)
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 10-Q Report Quarterly Report
- 8-K Event Auditor change
- 10-Q Report Quarterly Report
- NT 10-Q Other NT 10-Q
- 4 Open-market buy CEO and CFO bought 3,600 shares at $9.88 ($35,568)
- 4 Open-market buy CEO and CFO bought 5,400 shares at $8.98 ($48,492)
- 10-K Report Annual Report
- 4 Open-market buy CEO and CFO bought 3,600 shares at $9.10 ($32,760)
- 4 Open-market buy CEO and CFO bought 5,500 shares at $8.73 ($48,015)
- NT 10-K Other NT 10-K
- 4 Open-market buy CEO and CFO bought 2,500 shares at $12.51 ($31,275)
- 4 Open-market buy CEO and CFO bought 2,900 shares at an average $13.58 ($39,391)
- 4 Open-market buy CEO and CFO bought 3,400 shares at $12.95 ($44,030)
- 4 Open-market buy CEO and CFO bought 2,000 shares at $11.97 ($23,940)
- 4 Open-market buy CEO and CFO bought 2,400 shares at $11.36 ($27,264)
- 4 Open-market buy CEO and CFO bought 3,200 shares at $11.12 ($35,584)
Page 2 of 14 · 279 filings